← Markets

Relay Therapeutics, Inc.

RLAY · NASDAQ

Market closed$19.91$0.540000 (+2.79%)After hours $20.09 · +0.90%

Key statistics

Previous close$19.37
Open$19.00
Day high$20.31
Day low$18.90
52-week high$20.79
52-week low$3.03
Market cap3.48B
Volume2.10M
Average volume4.16M
P/E ratio-12.68
Forward P/E—
EPS-1.57
Dividend yield0.00%

Market context

Why it moved

Relay Therapeutics stock moved higher following an upgrade to "Strong-Buy" by Canaccord Genuity, building on positive momentum from recent encouraging mid-stage clinical trial data showing significant efficacy for its lead asset zovegalisib in vascular anomalies.

MarketbeatInstagramAbc7newsCfdrodeoWeather

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Relay Therapeutics closed up nearly 3%, approaching its 52-week high of $20.79, as bullish momentum from its zovegalisib pipeline continues to attract investor interest. The stock has been buoyed by May's Phase 2 ReInspire data showing a 60% volumetric response rate in vascular anomalies patients, with Barclays maintaining an Overweight rating and a $27 price target citing a ~$6B market opportunity and potential accelerated approval pathway. Broader healthcare sector tailwinds — including UBS upgrading the sector and flagging a recovering biotech M&A environment — added further support even as the XLV healthcare ETF retreated on the day.

2.7878

July 16, 2026Relay Therapeutics edged down after closing slightly lower, though the stock remains a focal point for investors following a fresh analyst initiation. Canaccord Genuity initiated coverage on July 16 with a Buy rating and a $29 price target, adding to a constructive analyst consensus with a mean price target of ~$25.38. The broader bullish case centers on zovegalisib, Relay's mutant-selective PI3Kα inhibitor, which posted a 60% volumetric response rate in vascular anomalies and attracted upgraded price targets from Barclays ($27, Overweight) and Citizens ($21, Outperform) in May. Regulatory feedback is expected in the second half of 2026, keeping clinical catalysts in view.

-0.7176

July 15, 2026Relay Therapeutics shares rose nearly 2%, supported by carry-through momentum from May's Phase 2 ReInspire data showing 60% of patients achieved meaningful lesion volume reduction with Zovegalisib in vascular anomalies. The gain came as broader markets rallied on a softer-than-expected June CPI print (headline inflation falling to 3.5%), which lifted sentiment across growth-oriented names, while the healthcare sector faced headwinds from earnings-related pressure on larger peers like Abbott and UnitedHealth. Trading volume came in well below average, suggesting the move reflected constructive sentiment rather than a major new catalyst.

1.8687

July 11, 2026Relay Therapeutics fell sharply, pulling back from its 52-week high as a wave of insider selling weighed on sentiment. The CEO, CFO, and R&D President each executed pre-scheduled Rule 10b5-1 sales totaling over $1.4 million in aggregate, drawing investor attention despite the planned nature of the transactions. This comes after a remarkable ~450% gain over the past year, with the stock having recently benefited from Russell Growth index inclusions, a $275M capital raise, JPMorgan's new overweight rating with a $28 target, and positive Phase 2 ReInspire trial data for lead asset zovegalisib in PIK3CA-driven vascular anomalies.

-3.5904

July 10, 2026Relay Therapeutics surged to a new 52-week high, buoyed by a wave of bullish analyst activity and favorable sector tailwinds. JPMorgan initiated coverage with an Overweight rating and a $28 price target, joining H.C. Wainwright ($28) and Guggenheim ($26) in citing zovegalisib — a mutant-selective PI3Kα inhibitor with Breakthrough Therapy Designation — as a potential multi-indication growth driver, following a 60% volumetric response rate in the Phase 2 ReInspire trial. The rally also coincided with broad biotech momentum, with Jim Cramer calling the sector 'the hottest group in the market' amid expectations of a deal-making surge under a more favorable FDA environment. Offsetting some enthusiasm, the CEO, CFO, and R&D President each executed pre-scheduled 10b5-1 share sales near current highs, though all plans were adopted in October 2025.

5.7056

July 9, 2026Relay Therapeutics closed modestly lower despite a wave of bullish catalysts, as broader market risk-off sentiment tied to U.S.-Iran tensions and surging oil prices weighed on equities. JPMorgan initiated coverage with an Overweight rating and a $28 price target, citing zovegalisib as a potential multi-indication growth driver across PI3K-driven vascular anomalies and beyond — adding to a growing analyst consensus of Strong Buy with targets ranging to $32. The stock touched a new 52-week high intraday and has surged ~450% over the past year, fueled by positive Phase 2 ReInspire trial data and recent Russell index inclusions. Multiple insider sales under pre-established 10b5-1 plans, including by CEO Sanjiv Patel and CFO Thomas Catinazzo, were disclosed near the highs but are viewed as routine given the stock's extraordinary run.

-0.5572

July 8, 2026Relay Therapeutics shares surged over 4%, touching a 52-week high of $20.19, as the broader biotech sector rode a wave of M&A enthusiasm following Jim Cramer's bullish call on CNBC declaring biotech "the hottest group in the market." Cramer cited a more favorable FDA regulatory environment and predicted a flood of dealmaking, with Eli Lilly and Gilead already actively acquiring late-stage assets — dynamics that lift sentiment across clinical-stage names like Relay. The healthcare sector (XLV) also touched its own 52-week high, reinforcing the rotation into health care that has outpaced tech for two consecutive weeks.

4.4444

July 7, 2026Relay Therapeutics rose, buoyed by continued momentum from its Zovegalisib pipeline and a favorable sector backdrop, as healthcare has been the market's best-performing sector for two consecutive weeks. The stock benefited from broader biotech sentiment lifting peers, with investors tracking Relay's late-stage breast cancer studies and its FDA Breakthrough Therapy designation for Zovegalisib in PIK3CA-mutant advanced breast cancer — a catalyst that has helped the stock gain over 43% this year.

1.3405

Investing.com · July 16, 2026Canaccord initiates Relay Therapeutics stock with buy ratingMoomoo · July 16, 2026CCORF Initiates Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $29Quiver Quantitative · May 21, 2026Relay Therapeutics Prices Underwritten Public Offering of Common Stock Raising Approximately $275 MillionClinical Trials Arena · May 20, 2026Relay Therapeutics reports initial findings from Phase II ReInspire trialInvesting News Network · May 20, 2026Relay Therapeutics Announces Pricing of Public Offering of Common StockInvestor's Business Daily · May 19, 2026This Biotech's Drug Just Wiped The Floor With ForecastsGlobeNewswire · May 5, 2026Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate UpdatesSimply Wall Street · April 28, 2026Relay Therapeutics Call Puts Zovegalisib Breast Cancer Prospects In Focus
Mt Newswire · July 16, 2026Canaccord Genuity Initiates Relay Therapeutics at Buy With $29 Price Target
Benzinga · July 16, 2026Canaccord Genuity Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target of $29
Mt Newswire · July 8, 2026Relay Therapeutics Insider Sold Shares Worth $331,131, According to a Recent SEC Filing
Mt Newswire · July 8, 2026Relay Therapeutics Insider Sold Shares Worth $943,736, According to a Recent SEC Filing
Mt Newswire · June 24, 2026Relay Therapeutics Insider Sold Shares Worth $1,583,145, According to a Recent SEC Filing
Benzinga · May 26, 2026Guggenheim Maintains Buy on Relay Therapeutics, Raises Price Target to $26
Mt Newswire · May 21, 2026Relay Therapeutics Prices $275 Million Public Offering
Benzinga · May 20, 2026Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $27

Peers

S&P 500SPX · $7,457.69-1.01%Axsome Therapeutics, Inc.AXSM · $230.00-2.97%Revolution Medicines, Inc.RVMD · $186.16+3.90%Incyte CorporationINCY · $117.25+0.51%IDEAYA Biosciences, Inc.IDYA · $36.01+0.22%Black Diamond Therapeutics, Inc.BDTX · $1.79-1.10%Kymera Therapeutics, Inc.KYMR · $115.77+1.56%Nurix Therapeutics, Inc.NRIX · $23.12+0.22%Prelude Therapeutics IncorporatedPRLD · $4.20+0.48%C4 Therapeutics, Inc.CCCC · $3.69+3.07%Monte Rosa Therapeutics, Inc.GLUE · $24.56+6.04%Janux Therapeutics, Inc.JANX · $16.26+2.65%